Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 75/100

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Key Takeaway: Autonomix Medical, Inc. (NASDAQ: AMIX) announced that its CEO, Brad Hauser, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025. The webinar aims to engage investors with discussions followed by a Q&A session. Autonomix is focused on advancing treatments for nerve-related diseases and is developing a first-in-class technology that may improve diagnostics and treatment approaches, particularly for conditions like pancreatic cancer. Their investigational technology has not yet received marketing clearance in the U.S.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a virtual investor webinar indicates company transparency and engagement with stakeholders.
  • Innovative technologies being developed could revolutionize treatment for nerve-related diseases.
  • The technology has potential applications in multiple areas, broadening market opportunities.

Full Press Release Details

Live video webcast on Thursday, August 21st at 1:00 PM ET
THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer will participate in a virtual investor webinar hosted by Ladenburg Thalmann on Thursday, August 21, 2025 and 1:00 PM ET.
The webinar will be moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research of Ladenburg Thalmann. Following the discussion, there will be a question and answer session. Interested participants may pre-submit questions to events@ladenburg.com ahead of the event.
To register for the webinar, please click here. The webinar will also be accessible on the Events page in the Investors section of the Company’s website (www.autonomix.com)
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

medical device company
Virtual Investor Webinar

Frequently Asked Questions

When is the Autonomix Medical investor webinar?

The investor webinar is on Thursday, August 21, 2025, at 1:00 PM ET.

Who will moderate the webinar?

Jeffrey S. Cohen will moderate the webinar.

How can participants submit questions for the webinar?

Participants can pre-submit questions to events@ladenburg.com.

What is the focus of Autonomix Medical, Inc.?

Autonomix focuses on advancing nerve-targeted medical device technologies.

What condition is initially targeted by Autonomix's technology?

The technology initially targets pain caused by pancreatic cancer.

Last updated: Aug 18, 2025